First People's Hospital

Preoperative lanreotide treatment (SUFAH200401A) is a Phase 2 clinical program sponsored by The First People's Hospital of Lianyungang investigating lanreotide, a somatostatin receptor 2 agonist, for acromegaly management. Lanreotide is marketed as MYTOLAC and is approved in Australia under multiple PBS codes by Amdipharm Mercury and Ipsen. The program focuses on preoperative use of this small-molecule therapeutic to optimize patient outcomes prior to surgical intervention. As of October 2009, the program remains active with ongoing clinical investigation. Lanreotide represents an established pharmacological approach to acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion. The preoperative treatment strategy aims to normalize hormone levels and improve surgical candidacy. Current regulatory status shows lanreotide approved in Australia since 2004, with clinical trial activity also documented in China. The competitive landscape includes multiple somatostatin receptor agonists and novel mechanisms in Phase 2 and Phase 3 development globally.

Acromegaly is a rare but serious endocrine disorder requiring multimodal treatment. Preoperative optimization with somatostatin receptor agonists like lanreotide can reduce perioperative morbidity, improve surgical outcomes, and enhance patient safety during transsphenoidal pituitary surgery. The unmet medical need centers on achieving rapid biochemical control and symptom reduction before definitive surgical intervention, particularly in patients with severe disease or comorbidities. Lanreotide's established mechanism and safety profile make it a clinically relevant option for this indication. The competitive landscape is intensifying, with Phase 3 programs including paltusotine (Crinetics), HS-19-647 (Camurus), and multiple other candidates, suggesting growing commercial interest in acromegaly therapeutics. The patient population, though small due to disease rarity, represents a high-value segment with significant unmet needs around perioperative management and long-term disease control. Preoperative treatment protocols could expand the addressable market for somatostatin agonists and establish new clinical practice standards.

Drug Class: Somatostatin receptor agonist (small-molecule)

Mechanism of Action: Lanreotide acts as a somatostatin receptor 2 agonist, suppressing growth hormone and insulin-like growth factor-1 (IGF-1) secretion from somatotroph adenomas.

Modality: Small-molecule

Brand Name: MYTOLAC

Route of Administration: Not yet disclosed in available data

Molecular Target: Somatostatin receptor 2

Related Therapies: Lanreotide Autogel 120 mg (Ipsen, approved); octreotide (established comparator); pegvisomant (growth hormone receptor antagonist); dopamine agonists

First Approval: Lanreotide approved in Australia from February 2004 onwards under multiple PBS codes

Patent Status: Not yet disclosed

Australia (TGA): Lanreotide approved and listed on the Australian Register of Therapeutic Goods under multiple PBS codes (11289E, 11315M, 11316N, 11513Y, 11527Q, 11736Q, 5777C, 5778D, 5779E, 6423C) by Amdipharm Mercury (Australia) Pty Limited (first listed 2004-02-01) and Ipsen Pty Ltd (first listed 2010-07-01, with additional listing 2018-04-01).

China (NMPA): Lanreotide in clinical trials; NCT04852679 documents ongoing trial activity. Additional clinical trials in China include NCT01666990, NCT02551575, NCT05524519, NCT06728189, and NCT07487597.

FDA (United States): Regulatory status not yet disclosed in available data.

EMA (Europe): Regulatory status not yet disclosed in available data.

PMDA (Japan): Regulatory status not yet disclosed in available data.

Strategic Implications: The First People's Hospital of Lianyungang's Phase 2 program targeting preoperative lanreotide treatment represents a focused clinical development strategy addressing a specific treatment window in acromegaly management. Preoperative optimization protocols could establish new clinical practice standards and expand the addressable patient population for somatostatin agonists beyond chronic maintenance therapy.

Competitive Implications: Lanreotide faces intensifying competition from multiple Phase 3 candidates and emerging mechanisms. However, its established regulatory approval in Australia and proven safety profile provide competitive advantages for preoperative indication development. The Phase 2 status suggests the program is in mid-stage development, with Phase 3 advancement potentially 2-4 years away if development proceeds on standard timelines.

Clinical Development Catalysts: Completion of NCT00993356 and related trials in China will generate efficacy and safety data supporting regulatory submissions. Positive preoperative outcomes data could support label expansion or new indication filings in additional markets.

Expected Milestones: Phase 2 trial completion, interim efficacy readouts, potential Phase 3 initiation, and regulatory submissions in China and other markets remain anticipated but not yet formally disclosed. The October 2009 milestone date suggests the program has been in development for over a decade, warranting clarification on current status and timeline expectations.